Clinical trials: Alzheimer Dementia
Alzheimer Disease, Healthy Aging
Developing an Artificial Intelligence System to Detect Cognitive Impairment
Alzheimer's disease dementia (AD) is a debilitating and prevalent neurodegenerative disease in older adults globally. Cognitive impairment, a hallmark of AD, is assessed through verbal tests that require high specialization, and…
- Conditions
- Alzheimer Disease, Healthy Aging, Mild Cognitive Impairment
- Trial name
- NCT05794451
- Where
- Israel
- Volunteers
- 3,413 people, healthy volunteers welcome
- Sponsor
- University of Haifa
Alzheimer Disease, Hypercholesterolemia
The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease
Some studies suggest that statin medications may be effective against Alzheimer's disease. However, this has not been proven. The purpose of this study is to evaluate the efficacy of pitavastatin in patients with mild to moderate…
- Trial name
- PIT-ROAD (NCT00548145)
- Testing
- Pitavastatin, cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Osaka University
Alzheimer's Disease, Brain Neoplasm
PET Scan of Brain Metabolism in Relation to Age and Disease
The main source of energy for the brain comes from a combination of oxygen and glucose (sugar). For brain cells to function normally they must receive a constant supply of these nutrients.
- Conditions
- Alzheimer's Disease, Brain Neoplasm, Niemann Pick Disease
- Trial name
- NCT00001972
- Testing
- 15 O Water
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer Disease, Battery
Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development
The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs.
- Trial name
- PharmacogWP3 (NCT01487395)
- Testing
- Donepezil .
- Where
- 3 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Alzheimer's Disease
Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment
The aim of this project is to follow cohort of patients with aMCI in order to establish whether there are distinct subgroups in terms of evolution or aetiology, with distinct memory profiles and profiles of mesiotemporal atrophy…
- Trial name
- NCT00684281
- Testing
- Neurological and neuropsychological consultation, MRI, Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Alzheimer's Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.
- Trial name
- NCT01028911
- Testing
- PF-03654746
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer
Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
- Conditions
- Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related
- Trial name
- NCT07116473
- Testing
- Acoramidis (AG10)
- Volunteers
- 250 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Alzheimer Disease
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
- Trial name
- NCT04079803
- Testing
- Simufilam 100 mg tablet, Simufilam 50 mg oral tablet
- Where
- 9 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer's Disease
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
- Trial name
- NCT06199037
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer Disease, Transcranial Magnetic Stimulation
Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer Disease
Randomized clinical trial, comparative and single blind aims to determine effects on cognition, psychological and behavioral symptoms and functionality of 5 Hz repetitive transcranial magnetic stimulation (rTMS) administered over…
- Trial name
- AD-EMTr (NCT03270137)
- Testing
- repetitive transcranial magnetic stimulation- IDLPFC, repetitive transcranial magnetic stimulation - Six regions
- Volunteers
- 19 people
- Sponsor
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Alzheimer's Disease
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
- Trial name
- SAVE (NCT02097056)
- Testing
- Donepezil HCL
- Where
- 13 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Eisai Korea Inc.
Alzheimer Disease
Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease
The long-term safety and efficacy of galantamine (12 mg bid) will be documented during a one year open-label treatment in subjects with Alzheimer's Disease who completed the GAL-INT-8 trial (up to 400 eligible patients).
- Trial name
- NCT00304629
- Testing
- galantamine
- Volunteers
- 241 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Amnestic
Deep Brain Stimulation Guided by Brain Mapping to Treat Cognitive Impairment
This trial is a 12-month safety and feasibility study, enrolling up to six participants. These participants will serve as their own controls, structured in multiple parts that follow an initial short-term stereo…
- Conditions
- Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Amnestic, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Memory Deficit
- Trial name
- NCT07887737
- Testing
- Abbott St Jude Medical Infinity™
- Volunteers
- 6 people
- Sponsor
- University of Texas Southwestern Medical Center
Mild Cognitive Impairment
Memory Improvement Through Nicotine Dosing (MIND) Study
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI.
- Trial name
- MIND (NCT02720445)
- Testing
- Nicotine Transdermal Patch
- Where
- 36 sites in United States
- Volunteers
- 348 people
- Sponsor
- University of Southern California
Alzheimer Disease, Dementia
Neurostimulation for Cognitive Enhancement in Alzheimer's Disease
The prevalence of Alzheimer's Disease (AD) is rising, but existing medications provide only modest control of cognitive decline and associated symptoms, and novel therapies are urgently needed.
- Trial name
- NICE-AD (NCT04404153)
- Testing
- tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Albert Einstein College of Medicine
Alzheimer's Disease, Mild Cognitive Impairment
Nicotinamide as an Early Alzheimer's Disease Treatment
The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in…
- Trial name
- NEAT (NCT03061474)
- Testing
- Nicotinamide
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of California, Irvine
Dementia, Dysphagia
Family Caregiver Online Survey (Dementia and Swallowing Difficulties)
The Family Caregiver Survey is a one-time, 30-minute, online survey for people living with and caring for a family member with dementia.
- Conditions
- Dementia, Dysphagia, Dementia Alzheimers, Dementia, Vascular
- Trial name
- NCT06471660
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of Oregon
Dementia Disorders, Mild Cognitive Impairment (MCI)
Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia
Memory problems can range from normal aging to mild cognitive impairment (MCI) to dementia. This study looks at three ways of measuring what is happening in the brain at each of these stages: a blood test (GFAP), a brain MRI…
- Trial name
- NCT07812480
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Alzheimer's Disease
" The Eyes Have it " : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease
Alzheimer's disease (AD) has a prolonged prodromal phase before the stage of dementia. Subtle executive cognitive function deficits can be detected at this early pre-dementia phase, more than 10 years before dementia.
- Trial name
- LYLO (NCT01630525)
- Testing
- Neuropsychological assessment, ophthalmologic checkup, Automated non-invasive oculometry
- Where
- 3 sites in France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.